Application of Multi-State Markov Models to Alzheimer's Disease Data

  • Qianwei Lin Shaanxi University of Chinese Medicine
  • Huiling Deng Shaanxi University of Chinese Medicine
DOI: https://doi.org/10.18686/aem.v12i1.353
Keywords: Multi-State Markov Model, Alzheimer's Disease, APOE4 Allele, Disease Progression, Probability of Metastasis

Abstract

Objective: To explore the impact of the probability of metastasis between stages, mean residence time and APOE4 allele count on disease progression during the progression of Alzheimer's disease. Methods: 3191 patients initially diagnosed with Alzheimer's disease in the Uniform Data Set UDS maintained by the National Alzheimer's Collaborative Center (NACC) were selected, and a multi-state Markov model with death as the outcome was developed based on the MMSE standard cut-off point delineation criteria with three stages of Alzheimer's disease: mild, moderate and severe. Results: The metastatic intensity and probability of metastatic death gradually increased as the disease progressed through mild, moderate and severe stages; the mean length of stay in mild, moderate and severe Alzheimer's disease patients was 2.905, 1.875 and 1.819 years, respectively; with one APOE4 allele [HR 1.176, 95% CI (1.031,1.340)] and [HR 1.426, 95%CI(1.202,1.693)] were risk factors for mild to moderate transfer. Conclusions: Alzheimer's disease has a long course with multi-stage progression, risk factors affecting disease progression are more complex, the APOE4 allele is a risk factor for Alzheimer's disease, and having 2 APOE4 alleles is a greater risk than 1 APOE4 allele.

References

[1] Cummings J, Lee G, Zhong K, et al. Alzheimer's disease drug development pipeline: 2021[J]. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2021, 7(1): e12179.

[2] Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer's disease[J]. The Lancet, 2021, 397(10284): 1577–1590.

[3] Zhao J, Fu Y, Yamazaki Y, et al. APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer’s disease patient iPSC-derived cerebral organoids[J]. Nature communications, 2020, 11(1): 1-14.

[4] Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician[J]. Journal of psychiatric research, 1975, 12(3): 189-198.

[5] Hughes CP, Berg L, Danziger W, et al. A new clinical scale for the staging of dementia[J]. The British journal of psychiatry, 1982, 140(6): 566-572.

[6] Jackson C. Multi-state modeling with R：the msm package (version 1.0). 2011.

[7] Andersen, PK, Wandall, E.N.S. & Pohar Perme, M. Inference for transition probabilities in non-Markov multi-state models. Lifetime Data Analysis (2022) 28:585–604.

[8] Zheng X, Xiong J, Zhang Y, et al. Multistate Markov model application for blood pressure transition among the Chinese elderly population: a quantitative longitudinal study[J]. BMJ open, 2022, 12(7): e059805.

[9] Taguchi A, Hara K, Tomio J, et al. Multistate markov model to predict the prognosis of high-risk human papillomavirus-related cervical lesions[J]. Cancers, 2020, 12(2): 270.

[10] Dessie ZG, Zewotir T, Mwambi H, et al. Modelling of viral load dynamics and CD4 cell count progression in an antiretroviral naive cohort: using a joint linear mixed and multistate Markov model[J]. BMC infectious diseases, 2020, 20(1): 1-14.

[11] Farahani MV, Dizaji PA, Rashidi H, et al. Application of Multi-State Model in Analyzing of Breast Cancer Data[J]. Journal of Research in Health Sciences, 2019, 19(4): e00465.

[12] Smith EMD, Eleuteri A, Goilav B, et al. A Markov Multi-State model of lupus nephritis urine biomarker panel dynamics in children: Predicting changes in disease activity[J]. Clinical Immunology, 2019, 198: 71-78.

[13] Wattmo C, Wallin AK, Minthon L. Progression of mild Alzheimer’s disease: knowledge and prediction models required for future treatment strategies[J]. Alzheimer's research & therapy, 2013, 5(5): 1-15.
Published
2023-03-21
Issue
Vol 12, No 1(2023)
Section
Original Research Article

Copyright (c) 2023 Qianwei Lin, Huiling Deng

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear

Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.